BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

754 related articles for article (PubMed ID: 15985560)

  • 1. Endogenous glucagon-like peptide 1 controls endocrine pancreatic secretion and antro-pyloro-duodenal motility in humans.
    Schirra J; Nicolaus M; Roggel R; Katschinski M; Storr M; Woerle HJ; Göke B
    Gut; 2006 Feb; 55(2):243-51. PubMed ID: 15985560
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of glucagon-like peptide-1(7-36)amide on antro-pyloro-duodenal motility in the interdigestive state and with duodenal lipid perfusion in humans.
    Schirra J; Houck P; Wank U; Arnold R; Göke B; Katschinski M
    Gut; 2000 May; 46(5):622-31. PubMed ID: 10764704
    [TBL] [Abstract][Full Text] [Related]  

  • 3. GLP-1 regulates gastroduodenal motility involving cholinergic pathways.
    Schirra J; Nicolaus M; Woerle HJ; Struckmeier C; Katschinski M; Göke B
    Neurogastroenterol Motil; 2009 Jun; 21(6):609-18, e21-2. PubMed ID: 19220754
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Regulation of islet hormone release and gastric emptying by endogenous glucagon-like peptide 1 after glucose ingestion.
    Salehi M; Vahl TP; D'Alessio DA
    J Clin Endocrinol Metab; 2008 Dec; 93(12):4909-16. PubMed ID: 18827000
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Exendin(9-39)amide is an antagonist of glucagon-like peptide-1(7-36)amide in humans.
    Schirra J; Sturm K; Leicht P; Arnold R; Göke B; Katschinski M
    J Clin Invest; 1998 Apr; 101(7):1421-30. PubMed ID: 9525985
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Involvement of endogenous glucagon-like peptide-1 in regulation of gastric motility and pancreatic endocrine secretion.
    Witte AB; Grybäck P; Jacobsson H; Näslund E; Hellström PM; Holst JJ; Hilsted L; Schmidt PT
    Scand J Gastroenterol; 2011 Apr; 46(4):428-35. PubMed ID: 21114428
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gastric emptying and release of incretin hormones after glucose ingestion in humans.
    Schirra J; Katschinski M; Weidmann C; Schäfer T; Wank U; Arnold R; Göke B
    J Clin Invest; 1996 Jan; 97(1):92-103. PubMed ID: 8550855
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differential effects of subcutaneous GLP-1 on gastric emptying, antroduodenal motility, and pancreatic function in men.
    Schirra J; Kuwert P; Wank U; Leicht P; Arnold R; Göke B; Katschinski M
    Proc Assoc Am Physicians; 1997 Jan; 109(1):84-97. PubMed ID: 9010920
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Endogenous GLP-1 regulates postprandial glycemia in humans: relative contributions of insulin, glucagon, and gastric emptying.
    Nicolaus M; Brödl J; Linke R; Woerle HJ; Göke B; Schirra J
    J Clin Endocrinol Metab; 2011 Jan; 96(1):229-36. PubMed ID: 21047924
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Glucagon-like peptide 1 inhibition of gastric emptying outweighs its insulinotropic effects in healthy humans.
    Nauck MA; Niedereichholz U; Ettler R; Holst JJ; Orskov C; Ritzel R; Schmiegel WH
    Am J Physiol; 1997 Nov; 273(5):E981-8. PubMed ID: 9374685
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Erythromycin antagonizes the deceleration of gastric emptying by glucagon-like peptide 1 and unmasks its insulinotropic effect in healthy subjects.
    Meier JJ; Kemmeries G; Holst JJ; Nauck MA
    Diabetes; 2005 Jul; 54(7):2212-8. PubMed ID: 15983224
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Glucagon-Like Peptide-1 Inhibits Prandial Gastrointestinal Motility Through Myenteric Neuronal Mechanisms in Humans.
    Halim MA; Degerblad M; Sundbom M; Karlbom U; Holst JJ; Webb DL; Hellström PM
    J Clin Endocrinol Metab; 2018 Feb; 103(2):575-585. PubMed ID: 29177486
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of small intestinal glucose on glycaemia, insulinaemia and incretin hormone release are load-dependent in obese subjects.
    Trahair LG; Marathe CS; Standfield S; Rayner CK; Feinle-Bisset C; Horowitz M; Jones KL
    Int J Obes (Lond); 2017 Feb; 41(2):225-232. PubMed ID: 27840416
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Postprandial gut hormone responses and glucose metabolism in cholecystectomized patients.
    Sonne DP; Hare KJ; Martens P; Rehfeld JF; Holst JJ; Vilsbøll T; Knop FK
    Am J Physiol Gastrointest Liver Physiol; 2013 Feb; 304(4):G413-9. PubMed ID: 23275610
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Separate and Combined Glucometabolic Effects of Endogenous Glucose-Dependent Insulinotropic Polypeptide and Glucagon-like Peptide 1 in Healthy Individuals.
    Gasbjerg LS; Helsted MM; Hartmann B; Jensen MH; Gabe MBN; Sparre-Ulrich AH; Veedfald S; Stensen S; Lanng AR; Bergmann NC; Christensen MB; Vilsbøll T; Holst JJ; Rosenkilde MM; Knop FK
    Diabetes; 2019 May; 68(5):906-917. PubMed ID: 30626611
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intestinal phase of human antro-pyloro-duodenal motility: cholinergic and CCK-mediated regulation.
    Katschinski M; Schirra J; Begliner C; Langbein S; Wank U; D'Amato M; Arnold R
    Eur J Clin Invest; 1996 Jul; 26(7):574-83. PubMed ID: 8864420
    [TBL] [Abstract][Full Text] [Related]  

  • 17. GIP and GLP-1 Receptor Antagonism During a Meal in Healthy Individuals.
    Gasbjerg LS; Helsted MM; Hartmann B; Sparre-Ulrich AH; Veedfald S; Stensen S; Lanng AR; Bergmann NC; Christensen MB; Vilsbøll T; Holst JJ; Rosenkilde MM; Knop FK
    J Clin Endocrinol Metab; 2020 Mar; 105(3):. PubMed ID: 32077470
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of subcutaneous glucagon-like peptide 1 (GLP-1 [7-36 amide]) in patients with NIDDM.
    Nauck MA; Wollschläger D; Werner J; Holst JJ; Orskov C; Creutzfeldt W; Willms B
    Diabetologia; 1996 Dec; 39(12):1546-53. PubMed ID: 8960841
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The glucagon-like peptide-1 metabolite GLP-1-(9-36) amide reduces postprandial glycemia independently of gastric emptying and insulin secretion in humans.
    Meier JJ; Gethmann A; Nauck MA; Götze O; Schmitz F; Deacon CF; Gallwitz B; Schmidt WE; Holst JJ
    Am J Physiol Endocrinol Metab; 2006 Jun; 290(6):E1118-23. PubMed ID: 16403774
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of physiological hyperglycemia on duodenal motility and flow events, glucose absorption, and incretin secretion in healthy humans.
    Kuo P; Wishart JM; Bellon M; Smout AJ; Holloway RH; Fraser RJ; Horowitz M; Jones KL; Rayner CK
    J Clin Endocrinol Metab; 2010 Aug; 95(8):3893-900. PubMed ID: 20501683
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 38.